BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 17225182)

  • 1. [18F-FDG-PET in therapy response of esophageal cancer].
    Wieder HA; Herrmann K; Ott K; Krause BJ
    Radiologe; 2007 Feb; 47(2):110-4. PubMed ID: 17225182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
    Piessen G; Petyt G; Duhamel A; Mirabel X; Huglo D; Mariette C
    Ann Surg; 2013 Jul; 258(1):66-76. PubMed ID: 23470576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer.
    van Heijl M; Omloo JM; van Berge Henegouwen MI; Hoekstra OS; Boellaard R; Bossuyt PM; Busch OR; Tilanus HW; Hulshof MC; van der Gaast A; Nieuwenhuijzen GA; Bonenkamp HJ; Plukker JT; Cuesta MA; Ten Kate FJ; Pruim J; van Dekken H; Bergman JJ; Sloof GW; van Lanschot JJ
    Ann Surg; 2011 Jan; 253(1):56-63. PubMed ID: 21233607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot study of serial FLT and FDG-PET/CT imaging to monitor response to neoadjuvant chemoradiotherapy of esophageal adenocarcinoma: correlation with histopathologic response.
    Gerbaudo VH; Killoran JH; Kim CK; Hornick JL; Nowak JA; Enzinger PC; Mamon HJ
    Ann Nucl Med; 2018 Apr; 32(3):165-174. PubMed ID: 29332233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer.
    Krause BJ; Herrmann K; Wieder H; zum Büschenfelde CM
    J Nucl Med; 2009 May; 50 Suppl 1():89S-96S. PubMed ID: 19380406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The added value of metabolic imaging with FDG-PET in oesophageal cancer: prognostic role and prediction of response to treatment.
    Bombardieri E
    Eur J Nucl Med Mol Imaging; 2006 Jul; 33(7):753-8. PubMed ID: 16733687
    [No Abstract]   [Full Text] [Related]  

  • 7. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
    Kukar M; Alnaji RM; Jabi F; Platz TA; Attwood K; Nava H; Ben-David K; Mattson D; Salerno K; Malhotra U; Kanehira K; Gannon J; Hochwald SN
    JAMA Surg; 2015 Jun; 150(6):555-62. PubMed ID: 25902198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of disease-free survival using relative change in FDG-uptake early during neoadjuvant chemoradiotherapy for potentially curable esophageal cancer: A prospective cohort study.
    Hagen PV; Heijl MV; van Berge Henegouwen MI; Boellaard R; Bossuyt PM; Kate FJ; Dekken HV; Hoekstra OS; Sloof GW; Lanschot JJ
    Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 27001344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can ¹⁸F-fluorodeoxyglucose positron emission tomography predict responses to neoadjuvant therapy in oesophageal cancer patients? A meta-analysis.
    Chen YM; Pan XF; Tong LJ; Shi YP; Chen T
    Nucl Med Commun; 2011 Nov; 32(11):1005-10. PubMed ID: 21886014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus.
    Malik V; Lucey JA; Duffy GJ; Wilson L; McNamara L; Keogan M; Gillham C; Reynolds JV
    J Nucl Med; 2010 Dec; 51(12):1863-9. PubMed ID: 21078796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of
    Sasaki K; Uchikado Y; Okumura H; Omoto I; Kita Y; Arigami T; Uenosono Y; Owaki T; Maemura K; Natsugoe S
    Anticancer Res; 2017 Feb; 37(2):859-864. PubMed ID: 28179343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02).
    Klaeser B; Nitzsche E; Schuller JC; Köberle D; Widmer L; Balmer-Majno S; Hany T; Cescato-Wenger C; Brauchli P; Zünd M; Pestalozzi BC; Caspar C; Albrecht S; von Moos R; Ruhstaller T
    Onkologie; 2009 Dec; 32(12):724-30. PubMed ID: 20016233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring of response to pre-operative chemoradiation in combination with hyperthermia in oesophageal cancer by FDG-PET.
    Westerterp M; Omloo JM; Sloof GW; Hulshof MC; Hoekstra OS; Crezee H; Boellaard R; Vervenne WL; ten Kate FJ; van Lanschot JJ
    Int J Hyperthermia; 2006 Mar; 22(2):149-60. PubMed ID: 16754598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional imaging for early prediction of response to chemoradiotherapy: 3'-deoxy-3'-18F-fluorothymidine positron emission tomography--a clinical application model of esophageal cancer.
    Chao KS
    Semin Oncol; 2006 Dec; 33(6 Suppl 11):S59-63. PubMed ID: 17178290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer.
    Levine EA; Farmer MR; Clark P; Mishra G; Ho C; Geisinger KR; Melin SA; Lovato J; Oaks T; Blackstock AW
    Ann Surg; 2006 Apr; 243(4):472-8. PubMed ID: 16552197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Incremental Value of Subjective and Quantitative Assessment of 18F-FDG PET for the Prediction of Pathologic Complete Response to Preoperative Chemoradiotherapy in Esophageal Cancer.
    van Rossum PS; Fried DV; Zhang L; Hofstetter WL; van Vulpen M; Meijer GJ; Court LE; Lin SH
    J Nucl Med; 2016 May; 57(5):691-700. PubMed ID: 26795288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment.
    Wieder HA; Brücher BL; Zimmermann F; Becker K; Lordick F; Beer A; Schwaiger M; Fink U; Siewert JR; Stein HJ; Weber WA
    J Clin Oncol; 2004 Mar; 22(5):900-8. PubMed ID: 14990646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting response to chemoradiotherapy in rectal and oesophageal cancer with 18F-FDG: prognostic value and possible role in patient management.
    Hindié E; Hennequin C; Moretti JL
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1576-82. PubMed ID: 17579856
    [No Abstract]   [Full Text] [Related]  

  • 19. The predictive value of 18F-FDG PET for pathological response of primary tumor in patients with esophageal cancer during or after neoadjuvant chemoradiotherapy: a meta-analysis.
    Cong L; Wang S; Gao T; Hu L
    Jpn J Clin Oncol; 2016 Dec; 46(12):1118-1126. PubMed ID: 27702836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction.
    Wieder HA; Ott K; Lordick F; Becker K; Stahl A; Herrmann K; Fink U; Siewert JR; Schwaiger M; Weber WA
    Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):1925-32. PubMed ID: 17680242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.